Cartilage Affecting Patents (Class 514/17.1)
  • Patent number: 11896642
    Abstract: Provided herein are synthetic bioconjugates comprising collagen-binding peptides covalently bound to chemically modified glycan backbones, compositions containing the same, and uses thereof.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 13, 2024
    Assignee: Symic Holdings, Inc.
    Inventors: John Eric Paderi, Glenn Prestwich, Katherine Allison Stuart, Harsha Kabra, Elvis Ikwa
  • Patent number: 11351223
    Abstract: The invention provides methods and compositions for the treatment of cartilage damage or arthritis by administration of a protease-resistant ANGPTL3 polypeptide with chondrogenic activity.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: June 7, 2022
    Assignee: Novartis AG
    Inventors: Jörg Goldhahn, Kristen Johnson, Celeste Scotti, Igor Vostiar
  • Patent number: 11041006
    Abstract: The present invention provides compositions for use in recovering and/or ameliorating deterioration of physiological functions due to aging. Provided are: a cell overexpressing GDF6 protein or an miR-17 family member; a composition for use in treating a senescence-related condition, containing GDF6 protein; a composition for use in treating a senescence-related condition, containing a human expression vector for GDF6 protein or an miR-17 family member; and a composition for use in treating a senescence-related condition, containing a cell secreting GDF6 protein.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: June 22, 2021
    Assignee: RIKEN
    Inventor: Hayato Kaneda
  • Patent number: 10532069
    Abstract: Compositions and methods are disclosed for the treatment of osteoarthritis. The compositions comprising combinations of hyaluronic acid, glucosamine, and chondroitin sulfate, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: January 14, 2020
    Assignee: DEPUY SYNTHES PRODUCTS, INC.
    Inventors: Brooks J. Story, Scott A. Wadsworth, William R. Parrish, Uri Herzberg, Donna Torres, Benjamin A. Byers, Julia Hwang, Dongling Su
  • Patent number: 10047123
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: August 14, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • Publication number: 20150141344
    Abstract: The present invention relates to a composition for repairing cartilage tissue, to a method for producing same, and to the use thereof. The present invention provides a composition for repairing cartilage tissue, which is obtained by mixing collagen and hyaluronic acid using a two-way syringe or a mixer, wherein the collagen has a diluted concentration of 5-60 mg/mL excepting water or a physiological phosphate buffer solution, and the hyaluronic acid has a diluted concentration of 5-20 mg/mL excepting water or a physiological phosphate buffer solution.
    Type: Application
    Filed: June 8, 2012
    Publication date: May 21, 2015
    Applicant: SEWON CELLONTECH CO., LTD.
    Inventors: Se Ken Yeo, Cheong Ho Chang, Ji Chul Yoo, Dong Sam Suh, Jun Keun Lee, Sang Hun Woo
  • Publication number: 20150133367
    Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.
    Type: Application
    Filed: April 26, 2013
    Publication date: May 14, 2015
    Inventor: Doron C. Greenbaum
  • Publication number: 20150126452
    Abstract: The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc. Disclosed are furthermore novel protein or peptide structures, nucleic acids encoding same and cloning and expression vectors suitable for carrying out the inventive method for assembling multimeric proteins or peptides.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 7, 2015
    Inventors: Stefan Schiller, Matthias Huber
  • Patent number: 8987205
    Abstract: Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: March 24, 2015
    Assignee: Wyeth LLC
    Inventors: Carl Ralph Flannery, Christopher John Corcoran, Bethany Annis Freeman, Lisa A. Collins-Racie
  • Patent number: 8987201
    Abstract: Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a bone-forming cell; increasing the expression level of one or more of a bone matrix protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell; enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a subject; also provided are antibodies directed against black bear parathyroid hormone (PTH) and functional fragments thereof.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: March 24, 2015
    Assignee: Michigan Technological University
    Inventor: Seth W. Donahue
  • Publication number: 20150065428
    Abstract: The invention is a method of applying a joint inducing protein preferably BMP-9 or BMP-3 to an ossification center in order to create a joint, articular cartilage, or an endochondral cap. The ossification center may be one that occurs naturally such as in the case of amputation, wound healing or fracture, or, it may be artificially induced by the application of an ossification center inducing protein, which may include other BMP family proteins such as BMP-2, BMP-4 or BMP-7. Further, this invention is a method of producing joints, or joint-like structures in vitro by application of BMP-9 to cells derived from tissue regions capable of producing ossification centers, such as digit-derived fibroblasts.
    Type: Application
    Filed: August 31, 2013
    Publication date: March 5, 2015
    Inventors: Ken Muneoka, Minqan Yan, Ling Yu
  • Patent number: 8969301
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: March 3, 2015
    Assignees: aTyr Pharma Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Publication number: 20150057229
    Abstract: A method for inhibiting cartilage degradation comprising administering to a subject a therapeutically effective amount of a polypeptide comprising or consisting of a Link_TSG6 polypeptide is disclosed
    Type: Application
    Filed: September 9, 2014
    Publication date: February 26, 2015
    Inventors: Anthony Day, Caroline Milner, Sheona Patricia Drummond
  • Patent number: 8940698
    Abstract: Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or cartilage composition into a cartilage defect.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: January 27, 2015
    Assignee: Vivex Biomedical, Inc.
    Inventor: Theodore I. Malinin
  • Patent number: 8927491
    Abstract: Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: January 6, 2015
    Assignee: DePuy Mitek, LLC
    Inventors: Benjamin A. Byers, Dongling Su, Julia Hwang
  • Patent number: 8927493
    Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: January 6, 2015
    Assignee: Kringle Pharma, Inc.
    Inventors: Katsuro Tomita, Hiroyuki Tsuchiya, Katsuhiko Kitaoka, Junsuke Nakase, Keigo Hanada, Kunio Matsumoto
  • Patent number: 8916517
    Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: December 23, 2014
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: David H. Coy, Jerome L. Maderdrut, Min Li
  • Publication number: 20140364372
    Abstract: A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 11, 2014
    Inventors: Dan DEUTSCH, Amir Haze, Anat Blumenfeld
  • Patent number: 8900579
    Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: December 2, 2014
    Assignee: Alethia Biotherapuetics Inc.
    Inventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
  • Patent number: 8895506
    Abstract: The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: November 25, 2014
    Assignee: DePuy Synthes Products, LLC
    Inventors: Venkata R. Garigapati, Dongling Su, Rehan Khanzada, Steven J. Sawamura
  • Publication number: 20140342983
    Abstract: The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGF?). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.
    Type: Application
    Filed: April 28, 2014
    Publication date: November 20, 2014
    Inventors: Marina D'Angelo, Abdulhafez Selim
  • Patent number: 8877712
    Abstract: Methods and compositions are described enhancing bone density or formation, including for stabilizing bone grafts, bone repair, joint replacement, and cartilage repair that includes providing a composition including Del-1 locally to a site for enhancing bone density or formation, or to a culture or chondrocytes or multipotent chondrocyte precursor cells, whereby survival or differentiation of chondrocytes at the site is enhanced, thereby ultimately enhancing bone density or formation. Methods and compositions for stimulating hair regrowth are also provided.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: November 4, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: George P Yang, Jonathan A. Mathy, Thomas Quertermous
  • Patent number: 8871710
    Abstract: This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. The compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The compositions can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 28, 2014
    Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH
    Inventors: Jens Pohl, Frank Ploeger
  • Publication number: 20140301983
    Abstract: This invention pertains to the field of hyaluronic acid-binding synthetic peptidoglycans and methods of forming and using the same.
    Type: Application
    Filed: May 24, 2012
    Publication date: October 9, 2014
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventors: Alyssa Panitch, Jonathan C. Bernhard, John E. Paderi, Shaili Sharma
  • Publication number: 20140303087
    Abstract: Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.
    Type: Application
    Filed: June 19, 2013
    Publication date: October 9, 2014
    Applicant: MEDIPOST CO., LTD.
    Inventors: Yoon-Sun YANG, Won IL Oh, Hong Bae Jeon, Mee Hyun Jung, Sang Young Jeong
  • Patent number: 8853361
    Abstract: The invention relates to a sterile preparation which can be implanted on or in organic tissues, comprising: a natural or modified globin material which is insoluble at physiological pH and/or a material obtainable from globin which has been modified to be soluble at physiological pH, the said materials being biocompatible and biodegradable in the organism; an agent selected from natural or synthetic polymeric adhesive agents, polymeric tissue enhancement or filling agents, more particularly an agent based on crosslinked hyaluronic acid or on polylactic acid, and a polymeric wound cicatrization agent, specifically oxidized cellulose; with the provisos that, if the preparation comprises the said material obtainable from globin modified so as to be at least partly soluble, the said polymeric adhesive agent, if present, is not hyaluronic acid or carboxymethylcellulose and the said polymeric enhancement or filling agent, if present, is an agent based on crosslinked hyaluronic acid, and that, if the preparation com
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: October 7, 2014
    Assignee: Khorionyx
    Inventor: Jean-Louis Tayot
  • Publication number: 20140288002
    Abstract: This disclosure provides extracellular matrix-binding synthetic peptidoglycans comprised of one or more synthetic peptides conjugated to a glycan and methods of their use.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Inventors: Alyssa Panitch, John Eric Paderi, Shaili Sharma, Katherine Allison Stuart, Nelda Marie Vazquez-Portalatin
  • Publication number: 20140289882
    Abstract: The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), MSCs, fibroblasts, hematopoietic stem cells, endothelian stem cells, adipocytes, chondrocytes, osteoblasts, osteoclasts and endothelial cells) into chondrogenic cells without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.
    Type: Application
    Filed: July 19, 2012
    Publication date: September 25, 2014
    Applicants: OREGON HEALTH AND SCIENCE UNIVERSITY, VIVOSCRIPT, INC.
    Inventors: Yong Zhu, Shili Wu, Jun Bao, Cong-Qiu Chu
  • Publication number: 20140256643
    Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 11, 2014
    Inventors: Kristen JOHNSON, Jian SHI
  • Publication number: 20140256641
    Abstract: Isolated polypeptides are disclosed comprising an amino acid sequence encoding a monomer of a fibrous polypeptide attached to a heterologous polysaccharide binding domain. Composites comprising same, methods of generating same and uses thereof are all disclosed.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 11, 2014
    Applicants: CollPlant Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Oded SHOSEYOV, Shaul Lapidot, Sigal Meirovitch, Daniel L. Siegel
  • Patent number: 8828937
    Abstract: The present invention is directed to an isolated peptide comprising or consisting of an amino acid sequence with an amino acid identity of at least 90% compared to mature human BMP2 with SEQ ID No. 1, characterized in that said amino acid sequence comprises at least two amino acid substitutions characterized in that a first amino acid substitution occurs at a position corresponding to N59, S88, E94, V99, K101 and/or N102 of SEQ ID No. 1 and to uses thereof.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: September 9, 2014
    Assignee: Haase Investments UG
    Inventors: Petra Seemann, Stefan Mundlos, Carsten Reissner, Georg Duda, Julia Zimmer
  • Patent number: 8828941
    Abstract: The present invention provides compositions of matter suitable for the prevention of and/or treatment of a spinal disorder and/or spinal pain, e.g., caused by and/or associated with intervertebral disc (IVD) degeneration, and methods of treatment of a spinal disorder and/or spinal pain. For example, the compositions of the present invention comprise a modulator of growth differentiation factor (GDF)-6 signaling sufficient to reduce or prevent or delay IVD degeneration and/or to enhance or induce IVD regeneration. The present invention also provides medical devices comprising such compositions, and methods of treatment making use of such compositions.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: September 9, 2014
    Inventors: Ashish Diwan, Divya Diwan
  • Publication number: 20140242140
    Abstract: Fabrication method for stratified and layered tissue to repair osteochondral defects. In a method of the present disclosure, the method comprises the step of applying a first direction magnetic field to a first quantity of a first collagen solution to align collagen within the first collagen solution in a first direction relative to the first direction magnetic field, forming a first layer of collagen. In a method of generating an aligned collagen layer of the present disclosure, the method comprises applying a first magnetic field at or greater than 0.1 Tesla to a layer of a first collagen solution defining a horizontal plane, within a temperature at or between 2° C. and 45° C., to generate an aligned collagen layer.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 28, 2014
    Applicant: Purdue Research Foundation
    Inventors: Corey P. Neu, Tyler A. Novak, Garrett Shannon
  • Patent number: 8815803
    Abstract: This invention provides a composition for increasing a body height of a patient with short stature or an individual other than patients with short stature. More specifically, the invention provides: a composition for increasing the body height of an individual comprising a guanyl cyclase B (GC-B) activator as an active ingredient, the composition being to be administered to an individual free from FGFR3 abnormality; a method for increasing the body height of an individual free from FGFR3 abnormality which comprises activating GC-B; a method for screening an agent for increasing the body height of an individual which comprises selecting an agent for increasing the body height using GC-B activity as an indication; and a method for extending a cartilage bone free from FGFR3 abnormality which comprises activating GC-B in an individual.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: August 26, 2014
    Inventors: Kazuwa Nakao, Akihiro Yasoda, Hidetomo Kitamura
  • Patent number: 8802626
    Abstract: Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and detects resulting from degenerative diseases such as osteochondritis dessicans.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: August 12, 2014
    Assignee: Stryker Corporation
    Inventors: David C. Rueger, Marjorie M. Tucker, An-Cheng Chang
  • Publication number: 20140221294
    Abstract: This invention relates to oral and intra-articular formulations based on sulphated hyaluronic acid which are effective in the treatment of degenerative osteoarthritis.
    Type: Application
    Filed: April 11, 2014
    Publication date: August 7, 2014
    Inventors: Lanfranco CALLEGARO, Davide RENIER
  • Publication number: 20140213524
    Abstract: A novel composition for regenerating a cartilage has been demanded, which can achieve a good effect of regenerating a hyaline cartilage that is a nearly normal cartilage without requiring the use of any transplanted cell. The present invention provides a composition for regenerating a cartilage, wherein (a) a monovalent metal salt of low endotoxin alginic acid and (b) SDF-1 are used in combination.
    Type: Application
    Filed: August 22, 2012
    Publication date: July 31, 2014
    Inventors: Norimasa Iwasaki, Atsushi Sukegawa, Akio Minami, Nobuo Ohzawa
  • Patent number: 8791071
    Abstract: Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or cartilage composition into a cartilage defect.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: July 29, 2014
    Assignee: Vivex Biomedical, Inc.
    Inventor: Theodore I. Malinin
  • Publication number: 20140193468
    Abstract: The invention generally relates to systems (i.e. constructs) for repairing cartilage and methods for preparing the same that introduce a bioactive agent into a culture medium, suspension, scaffold, solution incorporated into the pores of the scaffold, or combinations thereof. The introduction of a bioactive agent promotes production of neo-cartilage (i.e. immature hyaline cartilage) in the system, both ex-vivo and in-vivo.
    Type: Application
    Filed: March 13, 2014
    Publication date: July 10, 2014
    Applicant: HISTOGENICS CORPORATION
    Inventors: Laurence J. B. Tarrant, Sonya Shortkroff, Shuichi Mizuno, Akihiko Kusanagi, Toshimasa Tokuno, Robert Lane Smith
  • Patent number: 8772241
    Abstract: The present invention provides a peptide represented by formula (I) of X1-Leu-X2-Leu-X3 wherein X1 represents Glu or Asp, X2 represents His, Lys or Arg, X3 represents Asp or Glu, with Glu, Asp, Leu, His, Lys and Arg being respectively glutamic acid, aspartic acid, leucine, histidine, lysine and arginine; or a pharmaceutically acceptable salt thereof; a composition for the treatment or prevention of at least one selected from cartilage damage and arthritis, containing the same peptide or a pharmaceutically acceptable salt thereof as an active ingredient; and a composition containing the same peptide or a pharmaceutically acceptable salt thereof and TGF?1.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: July 8, 2014
    Assignee: Ensoltek Co., Ltd.
    Inventors: Hae Jin Kim, Je Wook Lee, Young Joon Kwon, Eun Joung Moon
  • Patent number: 8765675
    Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: July 1, 2014
    Assignee: Novartis AG
    Inventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
  • Patent number: 8759296
    Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: June 24, 2014
    Assignees: The Regents of The University of California, The United States of America as Represented by The Department of Veterans Affairs
    Inventors: Samuel S. Murray, Keyvan Behnam, Elsa J. Brochmann-Murray
  • Publication number: 20140170106
    Abstract: The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage.
    Type: Application
    Filed: November 8, 2013
    Publication date: June 19, 2014
    Inventors: Kelsey Jean Carvell, Ruth Cheng, Graham Smith, Drew Burdon
  • Patent number: 8709997
    Abstract: Subjects lacking Nfat1 display osteoarthritis in weight-bearing joints. Osteoarthritic changes associated with Nfat1 deficiency are characterized by articular cartilage degradation, articular chondrocyte proliferation/clustering, progressive articular surface destruction, periarticular chondro-osteophyte formation, and exposure of thickened subchondral bone. Methods of treating osteoarthritis, methods of diagnosis and early prediction of the onset of osteoarthritis, and methods for screening drug candidates that may be useful for treatment of osteoarthritis are presented.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: April 29, 2014
    Assignee: University of Kansas
    Inventor: Jinxi Wang
  • Patent number: 8710014
    Abstract: The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGF?). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: April 29, 2014
    Assignee: ProteaPex Therapeutics LLC
    Inventors: Marina D'Angelo, Abdulhafez Selim
  • Patent number: 8697139
    Abstract: Harvesting articular chondrocyte cells from a non-critical location of a patient and growing additional cells for transplantation into a damaged or diseased disc of the patient.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: April 15, 2014
    Inventor: Frank Martin Phillips
  • Publication number: 20140066376
    Abstract: Provided herein are compositions and methods related to promoting protection or repair of articular cartilage and/or musculoskeletal soft tissue by contacting the cartilage, tissues or cellular components thereof with a parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) receptor agonist or releasing factor.
    Type: Application
    Filed: August 20, 2013
    Publication date: March 6, 2014
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Randy N. Rosier, Michael J. Zuscik, Erik Sampson, Susan V. Bukata, J. Edward Puzas, Hani Awad
  • Patent number: 8652530
    Abstract: The instant invention is the storage of Type II collagen containing tissue in carbonated water. Such Type II collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals. Such Type II collagen is also useful for the prevention of arthritis in mammals. The instant invention is also a method for the preparation of a nutritional supplement that includes the steps of: (a) separating water-insoluble undenatured Type II collagen containing animal tissue from animal tissue not containing Type II collagen; (b) subdividing and sterilizing said tissue under conditions which do not change the original structure of the Type II collagen to produce a subdivided and sterilized product; (c) packaging the subdivided and sterilized product in carbonated water.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: February 18, 2014
    Assignee: Cartilast Corp.
    Inventor: Eugene R. Moore
  • Publication number: 20130337074
    Abstract: The present invention relates to a composition comprising, or consisting of 2-50 mg/ml hyaluronic acid, 0.1-500 mg/ml of biodegradable particles with an average mean particle diameter of 1 nm-500 ?m, 1 pg/ml-10 ?g/ml cytokines, where the concentrations specified are based in each case on the total volume (w/v) of the composition and where the cytokines are enclosed in the biodegradable particles, and to their use in the treatment of cartilage defects, for example traumatic cartilage defects or osteoarthrosis.
    Type: Application
    Filed: November 30, 2011
    Publication date: December 19, 2013
    Inventors: Kristin Andreas, Jochen Ringe, Michael Sittinger
  • Publication number: 20130324473
    Abstract: The invention relates to the preparation and provision of a gelling collagen composition that instantaneously forms a collagen matrix, and means for the preparation and use thereof, in particular as part of a therapeutic treatment.
    Type: Application
    Filed: January 26, 2012
    Publication date: December 5, 2013
    Applicant: AMEDRIX GmbH
    Inventor: Thomas Graeve